Clinical Trials Logo

Human Papillomavirus Positive clinical trials

View clinical trials related to Human Papillomavirus Positive.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03618134 Terminated - Clinical trials for Oropharyngeal Squamous Cell Carcinoma

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Start date: October 4, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies the side effects and how well stereotactic body radiation therapy and durvalumab with or without tremelimumab before surgery work in treating participants with human papillomavirus positive oropharyngeal squamous cell cancer. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy and durvalumab with or without tremelimumab before surgery may work better in treating participants with oropharyngeal squamous cell cancer.